Efficacy of alogliptin/metformin combination tablets(INISYNC combination tablets) in type 2 diabetic patients.

Efficacy of alogliptin/metformin combination tablets(INISYNC combination tablets) in type 2 diabetic patients. - Efficacy of alogliptin/metformin combination tablets(INISYNC combination tablets) in type 2 diabetic patients.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034599

Enrollment

120

Registered

2018-10-22

Start date

2018-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients who are taking out alogliptin/metformin combination tablets (INISYNC combination tablets) and outpatient.

Exclusion criteria

Exclusion criteria: 1)Patients with a history of lactic acidosis. 2)Patients with moderate or severe renal dysfunction(eGFR<45mL/min/1.73m2). 3)Patients with severe liver dysfunction such as active hepatitis and liver cirrhosis. 4)Patients with heart failure and acute myocardial infarction, pulmonary embolism such as advanced disability cardiovascular system and lung function. 5)Patients with excessive alcohol intake. 6)Patients with severe infections, before and after surgery, serious trauma. 7)Patient with malignant disease. 8)Pregnant women or patients who may be pregnant.

Design outcomes

Primary

Measure	Time frame
The changes in HbA1c from the start of administration up to 6 months	—

Secondary

Measure	Time frame
1)Body weight 2)Compliance 3)Comparison with pretreatment drugs	—

Countries

Japan

Contacts

Public ContactYuji Kawaguchi

Minami Osaka hospital Internal medicine

y.kawaguchi@minamiosaka.com0666850221

Outcome results